Australia's Proteomics International climbs on biomarker commercialisation deal

Proteomics International Laboratories

21/06/2022 02:05

** Shares of Proteomics International Laboratories  PIQ.AX 
rise as much as 5.8% to A$0.800, post their biggest intraday pct
gain since June 16 
    ** Medtech co says it will commercialise medical research
firm QIMR Berghofer's biomarkers that can test for oesophageal
adenocarcinoma  urn:newsml:reuters.com:*:nASX1V9qNP 
    ** Says tests will be targeted at patients with
pre-malignant condition Barrett's oesophagus, a form of
oesophageal cancer
    ** Stock down 35.8% this year, as of last close

 (Reporting by Tejaswi Marthi in Bengaluru)
 ((tejaswi.marthi@thomsonreuters.com))